Gastric cancer is a major cause of cancer deaths in the world. The outcome of large gastric tumors and those with lymph node involvement remains poor after surgical resection. The optimal adjuvant therapy after surgical resection remains to be determined. The most common strategies in the adjuvant treatment of gastric cancers include fluoropyrimidine-based chemotherapy with or without radiation. The introduction of capecitabine has largely replaced continuous-infusion 5-fluorouracil (5-FU) owing to its ease of administration. However, its efficacy is not proven in randomized phase III trials involving gastric cancers.
A research article published on August 7, 2010 in the World Journal of Gastroenterology addresses this question. In this retrospective review study, the authors examined the role of capecitabine with radiation and compared its efficacy to the 5-FU with radiation regimen and fluoropyrimidinebased chemotherapy alone.
This study showed that capecitabine with concurrent radiation was as effective as 5-FU with radiation or fluoropyrimidine-based chemotherapy alone without radiation when given as adjuvant treatment for locally advanced gastric cancer.
The result from this hypothesis-generating study provides the basis for a further prospective study in evaluating the role of radiation with concurrent capecitabine as adjuvant therapy in resected gastric cancers.
Reference: Tham CK, Choo SP, Poon DYH, Toh HC, Ong SYK, Tan SH, Wang MLC, Foo KF. Capecitabine with radiation is an effective adjuvant therapy in gastric cancers. World J Gastroenterol 2010; 16(29): 3709-3715
Correspondence to: Dr. Chee Kian Tham, Department of Medical Oncology, National Cancer Centre Singapore, 11 Hospital Drive, Singapore 169610, Singapore. firstname.lastname@example.org
Telephone: +65-64368000 Fax: +65-62272759
About World Journal of Gastroenterology
World Journal of Gastroenterology (WJG), a leading international journal in gastroenterology and hepatology, has established a reputation for publishing first class research on esophageal cancer, gastric cancer, liver cancer, viral hepatitis, colorectal cancer, and H. pylori infection and provides a forum for both clinicians and scientists. WJG has been indexed and abstracted in Current Contents/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch) and Journal Citation Reports/Science Edition, Index Medicus, MEDLINE and PubMed, Chemical Abstracts, EMBASE/Excerpta Medica, Abstracts Journals, Nature Clinical Practice Gastroenterology and Hepatology, CAB Abstracts and Global Health. ISI JCR 2009 IF: 2.092. WJG is a weekly journal published by WJG Press. The publication dates are the 7th, 14th, 21st, and 28th day of every month. WJG is supported by The National Natural Science Foundation of China, No. 30224801 and No. 30424812, and was founded with the name of China National Journal of New Gastroenterology on October 1, 1995, and renamed WJG on January 25, 1998.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.